Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Maternal Multiple Micronutrients Supplements

8 de junho de 2026 atualizado por: Nutrition International
In collaboration with the Federal Government of Nigeria and Bauchi State, Nutrition International (NI) conducted a three-year implementation research study to assess whether adherence solutions - developed through a human-centered designed (HCD) approach - could improve adherence to multiple micronutrient supplementation (MMS) among pregnant women in Nigeria. These set of adherence solutions focused on strengthening the capacity of healthcare workers and community members, improving nutrition counselling within antenatal care, and engaging pregnant women' family members to support consistent MMS intake.

Visão geral do estudo

Status

Concluído

Condições

Descrição detalhada

Research has shown that antenatal multiple micronutrient supplementation (MMS), a daily dose of 15 vitamins and minerals, is just as effective as iron and folic acid supplementation (IFAS) in preventing maternal anaemia, more effective at improving birth outcomes and is safe for mothers and babies.

In 2020, the World Health Organization (WHO) released an updated guidance recommending that implementation research (IR) be conducted in settings where the transition from IFAS to MMS is being considered in low- and middle- income countries. IR can help countries understand how to best design and implement effective intervention in real-life settings and can be used to identify and investigate challenges that prevent effective implementation.

In line with the WHO's recommendation, in 2021, the Nigeria Federal Ministry of Health approved the use of MMS during pregnancy and called for implementation research (IR) in the updated National Guidelines for the Prevention and Control of Micronutrient Deficiencies in Nigeria.

Based on national stakeholders' identification of a critical need for context-specific implementation evidence, efforts focused on understanding how MMS can be effectively delivered, accepted, and adhered to within the Nigerian health system, particularly in light of the implementation bottlenecks and adherence gaps previously documented in IFAS programs.

This IR project aims to evaluate implementation approaches on optimizing pregnant women's adherence to MMS. One of the components of this IR project is an outcome evaluation - the focus of this protocol - that seeks to answer the following research questions:

Primary research questions:

• Does implementation of these implementation approaches increase pregnant women's adherence to MMS?

Secondary research questions:

  • Are the implementation approaches acceptable to key stakeholders?
  • Does implementation of the implementation approaches increase the quality of care/nutrition counseling in ANC?

The implementation approaches focused on:

  • Strengthening the capacity building of healthcare workers and community members
  • Improving nutrition counselling integrated into ANC delivery with an emphasis on MMS adherence
  • Engaging pregnant woman's family members (husbands) and influential community members to support maternal health and nutrition

An outcome evaluation was completed using a cluster randomized controlled trial (cRCT) with cross-sectional baseline (prior to the introduction of the implementation approaches) and endline (approximately 2 years after the introduction of the introduction of the implementation approaches) surveys among pregnant women, their husbands and healthcare workers (HCWs) across the three Local Government Areas (LGAs) in Bauchi State. MMS was integrated into routine ANC across the state prior to the baseline assessment.

Nutrition International worked closely with the Bauchi state government to select 3 LGAs (Dass, Ganjuwa and Giade) representing the north, central and southern parts of the state. This decision was made taking into consideration state representation key criteria such as religious demographic, ANC attendance, security, IFA utilization and socio-economic distribution. These LGAs comprise a total of 42 wards all of which were designated as study clusters for the intervention and control arms. Out of these 42 wards, a simple random selection was used to randomly allocate 22 wards to the intervention arm and 20 to the control arm across the three target LGAs:

  • Control arm: Eligible pregnant women in these study sites receive MMS as part of their standard ANC.
  • Intervention arm: Eligible pregnant women in these study sites receive MMS alongside the implementation approaches as part of their standard ANC.

A third observational arm was selected from a separate LGA where MMS had not been introduced and IFAS continued to be the standard of care to help contextualise differences between the intervention and control arms.

Quantitative and qualitative data were collected from participants through interviewer-administered questionnaires and focus group discussions. The study measured adherence through several methods including self-reported daily consumption, average consumption rate over a three-month period, and a physical pill count by the data collector. Difference-in-difference analysis will be used to assess whether the implementation approaches increased MMS adherence at endline. Descriptive statistics will be used to determine whether the adherence solutions are acceptable to healthcare workers, pregnant women, and their husbands.

Tipo de estudo

Intervencional

Inscrição (Real)

2601

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Bauchi
      • Dass, Bauchi, Nigéria
        • Public health facilities in Dass
      • Ganjuwa, Bauchi, Nigéria
        • Public health facilities in Ganjuwa
      • Giade, Bauchi, Nigéria
        • Public health facilities in Giade

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

Pregnant/post-partum women

  • Women of reproductive age (15-49 years of age)
  • Pregnant or up to 3 months post-partum women
  • Having reportedly received at least one MMS bottle at least 30 days before start of data collection from a participating public health facility-
  • Provide consent for participation

Health Care Workers (HCWs)

  • HCWs providing ANC services including MMS and IFAs to pregnant women at the selected health facilities

Husbands

  • Husbands of the enrolled pregnant women At endline, the same criteria apply.

Exclusion Criteria:

  • Anemic pregnant women

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Sem intervenção: Braço de controle
Experimental: Intervention Arm
Eligible pregnant women received implementation approaches
Implementation approaches are human-centered designed strategies aimed at optimizing pregnant women's daily adherence to MMS.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Adherence to MMS
Prazo: At baseline and approximately 2 years after (endline)

Defined as "when pregnant women consume the right dose of multiple micronutrient supplementation (MMS) at the right time throughout pregnancy".

Measured through self-reported daily consumption, self-reported average consumption rate over a three-month period, and pill count.

At baseline and approximately 2 years after (endline)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Acceptability
Prazo: At baseline and approximately 2 years after (endline)

Defined as stakeholders' attitude towards MMS and its introduction as part of ANC. Assessed through surveys (Likert scale).

The Likert scale is a 5 point scale quantifying attitudes from "strongly agree" to "strongly disagree".

At baseline and approximately 2 years after (endline)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Babajide Adebisi, Nutrition International
  • Investigador principal: Jennifer Busch Hallen, Nutrition International

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

7 de março de 2024

Conclusão Primária (Real)

26 de maio de 2025

Conclusão do estudo (Real)

26 de maio de 2025

Datas de inscrição no estudo

Enviado pela primeira vez

14 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de junho de 2026

Primeira postagem (Real)

12 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Published IPD will be shared upon reasonable request

Prazo de Compartilhamento de IPD

May 2026 for 3 years.

Critérios de acesso de compartilhamento IPD

Access to the data will be restricted to the data collectors and study team, both of whom will sign a confidentiality agreement. When transmitting this data to investigators approved for this study, anonymized datasets will then be sent by encrypted zipped file in Stata format, The password to access these files will be communicated separately using email. The encryption keys will be transferred in the same way to co-investigators, if and as needed.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Implementation Approaches

Se inscrever